Included in the buy were Rex’s OptionElite retrievable vena cava filter, Cleaner rotational thrombectomy system and UltraStream chronic hemodialysis catheter, the company said.
“We are pleased that Argon Medical will continue in their leadership position delivering these established and tested technologies to the growing patient population undergoing treatment for venous disease,” Rex Medical prez Lindsay Carter said in a press release.
Previously, Argon had an exclusive agreement with Rex Medical to license and distribute the products, the company said. The acquisition included all IP associated with the products.
“Acquiring these differentiated technologies uniquely positions Argon Medical Devices as a market leader in the minimally invasive vascular therapy category. Building on the momentum already established as a licensee of these products, we are further focusing our efforts on the venous disease space, providing safe and effective tools for venous therapy, and strengthening our growth in strategic global markets,” Argon prez George Leondis said in prepared remarks.
Argon said the OptionElite is the only IVC filter FDA cleared for delivery through the popliteal vein, and the Cleaner rotational thrombectomy device is the only wall-contacting system FDA cleared for use in the peripheral vasculature.